Japanese generics giant Sawai is pulling out of the US market, agreeing a deal to divest its Upsher-Smith business to Taiwan’s Bora Pharmaceuticals in a deal worth a little over $200m. As Sawai explained its rationale for the move, Bora pointed to “significant opportunities” for its TWi commercial prescription unit arising from the acquisition.
Sawai is selling its US Upsher-Smith business to focus on Japan • Source: Shutterstock
Sawai Pharmaceutical has agreed to sell its Upsher-Smith Laboratories business to Taiwan’s Bora Pharmaceuticals in a deal worth up to $210m, bringing to an end a near seven-year sojourn in the US market for the Japanese generics giant.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.
After Amgen’s surprise launch of the first US biosimilar to Eylea last year, expectations around competition are being further upended with the news that Biocon Biologics has struck a settlement deal with Regeneron allowing it to launch its own aflibercept rival in the second half of 2026. Will other challengers follow suit?
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
Having failed in US patent litigation over Amgen’s Enbrel, Sandoz is taking an alternative approach in trying to get its Erelzi biosimilar to market in the US ahead of patent expiry in 2029: launching an antitrust attack against the originator for “unlawfully extending and entrenching its monopoly."
The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.
